Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2010-12-13
- Last Posted Date
- 2014-07-01
- Lead Sponsor
- Acorda Therapeutics
- Target Recruit Count
- 40
- Registration Number
- NCT01258387
- Locations
- ๐บ๐ธ
Vanderbilt University, Nashville, Tennessee, United States
๐บ๐ธThe Medical Group of Saint Joseph's, Atlanta, Georgia, United States
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis
- Conditions
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2012-03-02
- Lead Sponsor
- Acorda Therapeutics
- Target Recruit Count
- 177
- Registration Number
- NCT00654927
- Locations
- ๐จ๐ฆ
St. Michael's Hospital, Toronto, Ontario, Canada
๐บ๐ธShepherd Center, Atlanta, Georgia, United States
๐บ๐ธUniversity of Chicago, Chicago, Illinois, United States
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial
- Conditions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2012-02-28
- Lead Sponsor
- Acorda Therapeutics
- Target Recruit Count
- 214
- Registration Number
- NCT00649792
- Locations
- ๐บ๐ธ
Shepherd Center, Atlanta, Georgia, United States
๐บ๐ธUniversity of Rochester, Rochester, New York, United States
๐จ๐ฆUniversity of British Columbia, Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial
- Conditions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2012-02-27
- Lead Sponsor
- Acorda Therapeutics
- Target Recruit Count
- 269
- Registration Number
- NCT00648908
- Locations
- ๐บ๐ธ
Advanced Neurology Specialists, Great Falls, Montana, United States
๐บ๐ธOhio State University MS Center, Columbus, Ohio, United States
๐บ๐ธUniversity of Texas-Houston, Houston, Texas, United States
Study of Fampridine-SR Tablets in Multiple Sclerosis Patients
- First Posted Date
- 2007-06-07
- Last Posted Date
- 2016-02-04
- Lead Sponsor
- Acorda Therapeutics
- Target Recruit Count
- 240
- Registration Number
- NCT00483652
- Locations
- ๐บ๐ธ
Shepherd Center, Atlanta, Georgia, United States
๐บ๐ธAlta Bates Summit Medical Center - Research and Education Institute, Berkeley, California, United States
๐บ๐ธCAMC Health Education & Research Institute, Charleston, West Virginia, United States
Study of Oral Fampridine-SR in Multiple Sclerosis
- First Posted Date
- 2005-08-08
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- Acorda Therapeutics
- Target Recruit Count
- 300
- Registration Number
- NCT00127530
- Locations
- ๐บ๐ธ
Thomas Jefferson University Physicians, Philadelphia, Pennsylvania, United States
๐บ๐ธUniversity of Washington, MS Research Center, Seattle, Washington, United States
๐บ๐ธCleveland Clinical Foundation, Cleveland, Ohio, United States
Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis
- First Posted Date
- 2003-01-30
- Last Posted Date
- 2011-08-04
- Lead Sponsor
- Acorda Therapeutics
- Target Recruit Count
- 206
- Registration Number
- NCT00053417
- Locations
- ๐บ๐ธ
USC MS Comprehensive Care Center, Los Angeles, California, United States
๐บ๐ธShepherd Center, Atlanta, Georgia, United States
๐บ๐ธOhio State University, Columbus, Ohio, United States
Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury
- Conditions
- Interventions
- First Posted Date
- 2002-07-16
- Last Posted Date
- 2020-01-14
- Lead Sponsor
- Acorda Therapeutics
- Target Recruit Count
- 213
- Registration Number
- NCT00041717
- Locations
- ๐บ๐ธ
Advocate Christ Medical Center-Dept. of Physical Medicine & Rehabilitation-EMG, Oak Lawn, Illinois, United States
๐บ๐ธMontana Neuroscience, Missoula, Montana, United States
๐บ๐ธClinical Research Services, Bismarck, North Dakota, United States